CRISPR Therapeutics’ (CRSP) “Market Outperform” Rating Reiterated at JMP Securities
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “market outperform” rating reiterated by analysts at JMP Securities in a report released on Wednesday,Benzinga reports. They presently have a $86.00 target price on the stock. JMP Securities’ price objective would indicate a potential upside of 129.15% from the company’s previous close. A number of […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “market outperform” rating reiterated by analysts at JMP Securities in a report released on Wednesday,Benzinga reports. They presently have a $86.00 target price on the stock. JMP Securities’ price objective would indicate a potential upside of 129.15% from the company’s previous close. A number of […]
